Suchergebnisse - (Person:"Mo, Hongnan")

PubPharm (54)

21

Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China

enthalten in: Breast (Edinburgh, Scotland) | 2021

von Li, Y. | Li, Q. | Mo, H. | +16

22

Progress in systemic therapy for triple-negative breast cancer

enthalten in: Frontiers of medicine | 2021

von Mo, H. | Xu, B.

23

Comparison of capecitabine-based regimens with platinum-based regimens in Chinese triple-negative breast cancer patients with liver metastasis

enthalten in: Annals of translational medicine | 2021

von Chen, Y. | Guan, Y. | Wang, J. | +11

24

In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer : A Study of the National Cancer Center, China

enthalten in: Frontiers in oncology | 2021

von Li, Y. | Abudureheiyimu, N. | Mo, H. | +15

25

Risk Factors and Survival of Patients With Liver Metastases at Initial Metastatic Breast Cancer Diagnosis in Han Population

enthalten in: Frontiers in oncology | 2021

von Lin, S. | Mo, H. | Li, Y. | +14

26

Platinum-based chemotherapy in advanced triple-negative breast cancer : A multicenter real-world study in China

enthalten in: International journal of cancer | 2020

von Chen, Y. | Guan, Y. | Wang, J. | +13

27

CDK4/6 inhibitor sensitivity-related gene and application

enthalten in: Europäisches Patentamt | 2020

von MA FEI | MO HONGNAN | LI DAN

28

Appropriate arrangement of cancer treatment after COVID-19 epidemic peaks in China

enthalten in: Journal of cancer research and clinical oncology | 2020

von Mo, H. | Liu, B. | Ma, F.

29

Genome-wide chromosomal instability by cell-free DNA sequencing predicts survival in patients with metastatic breast cancer

enthalten in: Breast (Edinburgh, Scotland) | 2020

von Mo, H. | Wang, X. | Ma, F. | +7

30

Development and validation of a nomogram for predicting survival of advanced breast cancer patients in China

enthalten in: Breast (Edinburgh, Scotland) | 2020

von Lin, S. | Mo, H. | Li, Y. | +14